Posted by Michael Wonder on 23 Apr 2024
Acadia Pharmaceuticals announces trofinetide new drug submission for treatment of Rett syndrome has been accepted for filing and priority review by Health Canada
22 April 2024 - Acadia Pharmaceuticals today announced that Health Canada has accepted its new drug submission for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted priority review for Acadia’s submission.
The Health Canada filing is supported by results from the positive pivotal Phase 3 LAVENDER study evaluating the efficacy and safety of trofinetide versus placebo in 187 girls and young women with Rett syndrome.
